Integrating transcriptomics and network analysis-based multiplexed drug repurposing to screen drug candidates for M2 macrophage-associated castration-resistant prostate cancer bone metastases

Metastatic castration-resistant prostate cancer (CRPC) has long been considered to be associated with patient mortality. Among metastatic organs, bone is the most common metastatic site, with more than 90% of advanced patients developing bone metastases (BMs) before 24 months of death. Although pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Jinyuan, Jiang, Zhenglong, Ma, Tianyu, Li, Jie, Chen, Jiayang, Ye, Peizhi, Feng, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643318/
https://www.ncbi.nlm.nih.gov/pubmed/36389722
http://dx.doi.org/10.3389/fimmu.2022.989972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643318/
https://www.ncbi.nlm.nih.gov/pubmed/36389722
http://dx.doi.org/10.3389/fimmu.2022.989972

Ejemplares similares